

COVID-19 vaccines under evaluation

The Human Medicines Committee (CHMP) at EMA is evaluating preliminary data on the following COVID-19 candidate vaccines



Vaccine	Developer	Description	Status	Start of the evaluation	More information
ChAdOx1-SARS-CoV-2	AstraZeneca, in collaboration with the University of Oxford	COVID-19 Vaccine AstraZeneca is made up of an adenovirus that has been modified to contain the gene coding spike protein. The vaccine delivers the SARS-CoV-2 gene into cells that will use the gene to produce the spike protein. The immune system will treat this protein as foreign and produce antibodies and T cells against it	Conditional marketing authorisation application under evaluation	12/01/2021	<ul style="list-style-type: none"> https://www.ema.europa.eu/en/news/ema-starts-first-rolling-review-covid-19-vaccine-eu https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-astrazeneca
Ad26.CO2.S	Janssen Vaccines & Prevention B.V	Ad26.CO2.S contains genetic instructions for the spike (S) protein which is present on the surface of SARS-CoV-2 coronavirus. When a person is given the vaccine, their cells will read the genetic instructions and produce the spike protein. The immune system will then treat this protein as foreign and produce antibodies and T cells against it	Rolling review	01/12/2020	https://www.ema.europa.eu/en/news/ema-starts-rolling-review-janssens-covid-19-vaccine-ad26cov2s